Zerit

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
27-03-2019
Opinber matsskýrsla Opinber matsskýrsla (PAR)
02-06-2016

Virkt innihaldsefni:

stavudine

Fáanlegur frá:

Bristol-Myers Squibb Pharma EEIG

ATC númer:

J05AF04

INN (Alþjóðlegt nafn):

stavudine

Meðferðarhópur:

Antivirals for systemic use

Lækningarsvæði:

HIV Infections

Ábendingar:

Hard capsulesZerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (over the age of three months) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible.Powder for oral solutionZerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (from birth) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible.

Vörulýsing:

Revision: 31

Leyfisstaða:

Withdrawn

Leyfisdagur:

1996-05-08

Upplýsingar fylgiseðill

                                57
B. PACKAGE LEAFLET
Approved
1.0
v
58
PACKAGE LEAFLET: INFORMATION FOR THE USER
ZERIT 15 MG HARD CAPSULES
Stavudine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Zerit is and what it is used for
2.
What you need to know before you take Zerit
3.
How to take Zerit
4.
Possible side effects
5.
How to store Zerit
6.
Contents of the pack and other information
1.
WHAT ZERIT IS AND WHAT IT IS USED FOR
Zerit belongs to a particular group of antiviral medicines, also known
as antiretrovirals, called
nucleoside reverse transcriptase inhibitors (NRTIs).
These are used to treat Human Immunodeficiency Virus (HIV) infection.
This medicinal product, in combination with other antiretrovirals,
reduces the HIV viral load and
keeps it at a low level. It also increases CD4 cell counts. These CD4
cells play an important role in
maintaining a healthy immune system to help fight infection. Response
to treatment with Zerit varies
between patients. Your doctor will therefore be monitoring the
effectiveness of your treatment.
Zerit may improve your condition, but it is not a cure for your HIV
infection. You can still pass on
HIV when taking this medicine, although the risk is lowered by
effective antiretroviral therapy.
Discuss with your doctor the precautions needed to avoid infecting
other people.
During treatment, other infections linked to a weakened immunity
(opportunistic infections) may arise.
These will require specific and sometimes preventive treatment.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZERIT

                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Approved
1.0
v
2
1.
NAME OF THE MEDICINAL PRODUCT
Zerit 15 mg hard capsules
Zerit 20 mg hard capsules
Zerit 30 mg hard capsules
Zerit 40 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Zerit 15 mg hard capsules
Each hard capsule contains 15 mg of stavudine.
Excipients with known effect
Each hard capsule contains 80.84 mg of lactose anhydrous.
Each hard capsule contains 40.42 mg of lactose monohydrate.
Zerit 20 mg hard capsules
Each hard capsule contains 20 mg of stavudine.
Excipients with known effect
Each hard capsule contains 121.30 mg of lactose anhydrous.
Each hard capsule contains 60.66 mg of lactose monohydrate.
Zerit 30 mg hard capsules
Each hard capsule contains 30 mg of stavudine.
Excipients with known effect
Each hard capsule contains 121.09 mg of lactose anhydrous.
Each hard capsule contains 60.54 mg of lactose monohydrate.
Zerit 40 mg hard capsules
Each hard capsule contains 40 mg of stavudine.
Excipients with known effect
Each hard capsule contains 159.06 mg of lactose anhydrous.
Each hard capsule contains 79.53 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule.
Zerit 15 mg hard capsules
The hard capsule is red and yellow, opaque and imprinted with
“BMS” over a BMS code “1964” on
one side and “15” on the other side.
Zerit 20 mg hard capsules
The hard capsule is brown, opaque and imprinted with “BMS” over a
BMS code “1965” on one side
and “20” on the other side.
Zerit 30 mg hard capsules
The hard capsule is light and dark orange, opaque and imprinted with
“BMS” over a BMS code
“1966” on one side and “30” on the other side.
Approved
1.0
v
3
Zerit 40 mg hard capsules
The hard capsule is dark orange, opaque and imprinted with “BMS”
over a BMS code “1967” on one
side and “40” on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Zerit is indicated in combination with other antiretroviral medicinal
products for the treatmen
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 27-03-2019
Vara einkenni Vara einkenni búlgarska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla búlgarska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 27-03-2019
Vara einkenni Vara einkenni spænska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla spænska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 27-03-2019
Vara einkenni Vara einkenni tékkneska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla tékkneska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 27-03-2019
Vara einkenni Vara einkenni danska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla danska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 27-03-2019
Vara einkenni Vara einkenni þýska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla þýska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 27-03-2019
Vara einkenni Vara einkenni eistneska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla eistneska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 27-03-2019
Vara einkenni Vara einkenni gríska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla gríska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 27-03-2019
Vara einkenni Vara einkenni franska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla franska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 27-03-2019
Vara einkenni Vara einkenni ítalska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla ítalska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 27-03-2019
Vara einkenni Vara einkenni lettneska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla lettneska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 27-03-2019
Vara einkenni Vara einkenni litháíska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla litháíska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 27-03-2019
Vara einkenni Vara einkenni ungverska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla ungverska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 27-03-2019
Vara einkenni Vara einkenni maltneska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla maltneska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 27-03-2019
Vara einkenni Vara einkenni hollenska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla hollenska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 27-03-2019
Vara einkenni Vara einkenni pólska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla pólska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 27-03-2019
Vara einkenni Vara einkenni portúgalska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla portúgalska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 27-03-2019
Vara einkenni Vara einkenni rúmenska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla rúmenska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 27-03-2019
Vara einkenni Vara einkenni slóvakíska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 27-03-2019
Vara einkenni Vara einkenni slóvenska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla slóvenska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 27-03-2019
Vara einkenni Vara einkenni finnska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla finnska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 27-03-2019
Vara einkenni Vara einkenni sænska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla sænska 02-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 27-03-2019
Vara einkenni Vara einkenni norska 27-03-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 27-03-2019
Vara einkenni Vara einkenni íslenska 27-03-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 27-03-2019
Vara einkenni Vara einkenni króatíska 27-03-2019
Opinber matsskýrsla Opinber matsskýrsla króatíska 02-06-2016

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu